We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) about the efficacy and safety findings of the KEYNOTE-224 study (Clinical Trial Identifier: NCT02702414).
The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
- What was previously known about the use of pembrolizumab in the treatment of patients with advanced hepatocellular carcinoma (HCC)? (0:37)
- Could you tell us a little about the aims and design of KEYNOTE-224? (2:54)
- What were the efficacy and safety findings of the study? (4:50)
Disclosures: Jean-Luc Van Laethem has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
Share this Video
Related Videos In Gastrointestinal Oncology
Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]
Alvaro Arjona-Sanchez, ESMO 2022: HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant HIPEC in patients with locally advanced colon cancer
Peritoneal metastasis in locally advanced colon cancer has a poor prognosis from 3 years post surgical resection. Dr Alvaro Arjona-Sanchez (Institute of Biomedical Research IMIBIC, University Hospital Reina Sofia, Cordoba, Spain) joins touchONCOLOGY to discuss the HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally […]
Myriam Chalabi, ESMO 2022: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study
Neoadjuvant immunotherapy has shown promising responses in several cancer types. In this touchONCOLOGY interview Dr Myriam Chalabi (Netherlands Cancer Institute, Amsterdam, Netherlands) discusses the NICHE-2 study results, investigating patients with non-metastatic deficient DNA mismatch repair (dMMR) colon cancer, treated with one dose of ipilimumab and two doses of nivolumab and underwent surgery ≤6 weeks of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!